ZURA — Zura Bio Ltd

—
Nasdaq · Health Care · Biotechnology · CIK 1855644 ·
Last close
$1.03
Market Cap
$99.70M
52W High
$7.44
52W Low
$0.93
ADV30
7,087,210
Next earnings
2026-10-27

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -28,773,000 -25,825,000 194,629,000 187,652,000 16,969,000
Jun 2026 0 — -29,321,000 -26,304,000 213,403,000 205,134,000 16,318,000
Mar 2026 0 — -25,499,000 -24,223,000 228,641,000 225,594,000 11,745,000
Dec 2025 0 — -18,411,000 -17,175,000 113,948,000 109,407,000 12,410,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-81,600,000
Investing CF
$-90,000
Financing CF
$130,325,000
CapEx
$-90,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.84
As of
2026-11-01

Balance + Analyst (yfinance extras)

Retained Earnings
$-300,899,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-102,004,000
Pretax Income TTM
$-94,829,000
Interest Exp TTM
—
Analysts
5

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -75,246,000 -68,650,000 113,948,000 12,410,000 101,538,000 -64,815,000
Dec 2024 0 -55,189,000 -52,403,000 179,533,000 19,514,000 146,815,000 -28,076,000
Dec 2023 0 -62,638,000 -60,360,000 100,843,000 21,292,000 59,330,000 -15,054,000
Dec 2022 0 -27,162,000 -25,738,000 5,262,000 27,318,000 -32,056,000 -1,202,000

TTM Snapshot

Revenues TTM
$-6,041,000
NetIncome TTM
$-85,742,000
OpCashFlow TTM
—
Assets (Latest)
$213,403,000
Forward EPS
$-0.68

Max Pain — expiry 2026-12-18

max pain strike: $1.00 · spot: $0.96 · call oi: 656 · put oi: 1,684
Expected Move to 2026-12-18: ±$0.24 (24.87%) — implied range $0.72 – $1.20 · ATM straddle on $1.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
ARMP Armata Pharmaceuticals, Inc. $98.93M $2.66 —
VYGR Voyager Therapeutics, Inc. $94.59M $1.52 —
CMPX Compass Therapeutics, Inc. $109.26M $0.61 —
MOLN MOLECULAR PARTNERS AG $109.55M $2.86 —
LENZ LENZ Therapeutics, Inc. $109.97M $3.50 —

News headlines (Yahoo Finance, 1h cache)

Zura Bio discontinues tibulizumab in HS after Phase II trial failure
2026-11-10 10:59 · Yahoo
Zura Bio Discontinues Hidradenitis Suppurativa Development After Phase 2 Tibulizumab Trial Misses Endpoints
2026-11-09 15:59 · Yahoo
Zura Bio Provides Clinical Update on Phase 2 TibuSHIELD Study of Tibulizumab (ZB-106) in Hidradenitis Suppurativa
2026-11-09 12:00 · Yahoo
Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-10-27 22:00 · Yahoo
Zura Bio Reports Third Quarter 2026 Financial Results and Recent Corporate Updates
2026-10-27 11:30 · Yahoo
This biotech stock is a top pick at Guggenheim
2026-10-07 08:00 · Yahoo
Zura Bio to Participate in the Cantor Global Healthcare Conference
2026-08-31 20:30 · Yahoo
Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer
2026-05-13 11:30 · Yahoo
Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates
2026-05-07 11:30 · Yahoo
Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2026-05-14 11:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.